{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418519851387776.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1161/circheartfailure.115.002285"}},{"identifier":{"@type":"URI","@value":"https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.115.002285"}}],"dc:title":[{"@value":"Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction"}],"dcterms:alternative":[{"@value":"Findings From the Swedish Heart Failure Registry"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title>Background—</jats:title>\n            <jats:p>In heart failure and reduced ejection fraction, the prognostic role of heart rate (HR) in atrial fibrillation (AF) is unknown and the effectiveness of β-blockers has recently been questioned in AF.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results—</jats:title>\n            <jats:p>\n              A total of 18 858 patients with heart failure and reduced ejection fraction registered with Swedish Heart Failure Registry were included in this study: patients with sinus rhythm (SR; n=11 466) and patients with AF (n=7392). The outcome measure was all-cause mortality. Compared with HR ≤60 beats per minute, the adjusted hazard ratios for mortality in SR were 1.26 for HR=61 to 70 beats per minute, 1.37 for HR=71 to 80 beats per minute, 1.52 for HR=81 to 90 beats per minute, 1.63 for HR=91 to 100 beats per minute, and 2.69 for HR >100 beats per minute. However, in AF, the hazard ratio increased only for HR >100 beats per minute (1.30;\n              <jats:italic>P</jats:italic>\n              =0.001). β-blocker use was associated with reduced mortality in SR (hazard ratio, 0.77;\n              <jats:italic>P</jats:italic>\n              =0.011) and in AF (hazard ratio, 0·71;\n              <jats:italic>P</jats:italic>\n              <0.001). For β-blocker use in SR, the hazard ratio gradually increased with HR increment, whereas in AF, the hazard ratio significantly increased only for HR >100 beats per minute (1.29;\n              <jats:italic>P</jats:italic>\n              =0.003) compared with HR ≤60 beats per minute.\n            </jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions—</jats:title>\n            <jats:p>In patients with heart failure and reduced ejection fraction, a higher HR was associated with increased mortality in SR, but in AF, this is true only for HR >100 beats per minute. β-blocker use was associated with reduced mortality both in SR and in AF.</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381418519851387780","@type":"Researcher","foaf:name":[{"@value":"Shi-Jun Li"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418519851387779","@type":"Researcher","foaf:name":[{"@value":"Ulrik Sartipy"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418519851387649","@type":"Researcher","foaf:name":[{"@value":"Lars H. Lund"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418519851387777","@type":"Researcher","foaf:name":[{"@value":"Ulf Dahlström"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418519851387778","@type":"Researcher","foaf:name":[{"@value":"Martin Adiels"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418519851387648","@type":"Researcher","foaf:name":[{"@value":"Max Petzold"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]},{"@id":"https://cir.nii.ac.jp/crid/1381418519851387776","@type":"Researcher","foaf:name":[{"@value":"Michael Fu"}],"jpcoar:affiliationName":[{"@value":"From the Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden (S.-J.L., M.F.); Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China (S.-J.L.); Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden (U.S.); Department of Molecular Medicine and Surgery (U.S.), Unit of Cardiology, Department of Medicine (L.H.L.), Karolinska Institute, Stockholm, Sweden; Department of Cardiology and..."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"19413289"},{"@type":"EISSN","@value":"19413297"}],"prism:publicationName":[{"@value":"Circulation: Heart Failure"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2015-09","prism:volume":"8","prism:number":"5","prism:startingPage":"871","prism:endingPage":"879"},"reviewed":"false","url":[{"@id":"https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.115.002285"}],"createdAt":"2015-09-15","modifiedAt":"2024-05-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360009142594326144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168805945216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Transfusion‐associated circulatory overload and high blood pressure: A multicentre retrospective study in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232154325376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Gene therapy to terminate tachyarrhythmias"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588380594597120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Contemporary Use of β‐Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694368207969152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Heart rate determines the beneficial effects of beta-blockers on cardiovascular outcomes in patients with heart failure and atrial fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001288105678976","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"心房細動の薬物によるレートコントロール療法"},{"@language":"en","@value":"Copyright and licensing of E-journals:"}]},{"@id":"https://cir.nii.ac.jp/crid/1390002184880550656","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Differential Response to Heart Rate Reduction by Carvedilol in Heart Failure and Reduced Ejection Fraction Between Sinus Rhythm and Atrial Fibrillation　― Insight From J-CHF Study ―"},{"@value":"Differential Response to Heart Rate Reduction by Carvedilol in Heart Failure and Reduced Ejection Fraction between Sinus Rhythm and Atrial Fibrillation—Insight from J-CHF Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390002184888888576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"High Nighttime Heart Rate is Associated with Increased Risk of All-Cause Mortality in Patients with Heart Failure and Reduced Ejection Fraction"}]},{"@id":"https://cir.nii.ac.jp/crid/1390002184888990080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Combination of Landiolol and Levosimendan in Patients with Decompensated Heart Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390011030550455168","@type":"Article","resourceType":"letter","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk　― Reply ―"},{"@value":"JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias"},{"@value":"JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk"},{"@value":"<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias"}]},{"@id":"https://cir.nii.ac.jp/crid/1390283659850324736","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"VI. Rate Control Therapy: Therapeutic Target and Use Drugs"},{"@language":"ja","@value":"VI．レートコントロール療法：治療目標と使用薬物"},{"@value":"レートコントロール療法 : 治療目標と使用薬物"},{"@language":"ja-Kana","@value":"レートコントロール リョウホウ : チリョウ モクヒョウ ト シヨウ ヤクブツ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390285300184243456","@type":"Article","resourceType":"letter","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Is High Heart Rate Always Harmful to Heart Failure Patients?"},{"@value":"Is High Heart Rate Always Harmful to Heart Failure Patients?　― Reply ―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390290172818748160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure"},{"@value":"Guideline focused update on diagnosis and treatment of acute and chronic heart failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390292505528970368","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Minor Allele of GJA1 Gene Polymorphism Is Associated with Higher Heart Rate During Atrial Fibrillation"},{"@language":"ja","@value":"GJA1遺伝子多型マイナーアレルは心房細動中の高心拍数に関与している"}]},{"@id":"https://cir.nii.ac.jp/crid/1390294719108144256","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Association Between Periprocedural Heart Rate Trend and Postprocedural Worsening Heart Failure in Patients Receiving Catheter Ablation for Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564227306263808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure　― Digest Version ―"},{"@value":"JCS GUIDELINES : JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure : Digest Version"},{"@value":"Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure- Digest Version"},{"@value":"JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version"},{"@value":"JCS 2017/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure — digest version —"},{"@value":"JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure"},{"@value":"JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure- digest version. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure- digest version"},{"@value":"Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version"},{"@value":"Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. Guidelines for diagnosis and treatment of acute and chronic heart failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390852105054235392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies"}]},{"@id":"https://cir.nii.ac.jp/crid/1391693801399770752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Different Impact of Resting Heart Rate on Adverse Events in Paroxysmal and Sustained Atrial Fibrillation　― The Fushimi AF Registry ―"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1161/circheartfailure.115.002285"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-19-0342_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-20-0567_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1007/s40801-019-0149-1_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1111/vox.13063_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-20-0198_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1002/joa3.12714_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-20-0910_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1016/j.cardfail.2021.04.023_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-20-1212_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.5105/jse.42.63_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1080/14779072.2022.2085686_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1002/cpt.3496_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-21-0431_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.5105/jse.38.221_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circrep.cr-22-0108_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1536/ihj.19-420_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1253/circrep.cr-20-0008_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1038/s41440-019-0289-4_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.1536/ihj.19-403_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"},{"@type":"CROSSREF","@value":"10.2169/naika.108.234_references_DOI_OQdiqdMUHRZMH0vABxJsNRExtAH"}]}